Clinical

A real-world study showed that ruxolitinib is a safe treatment for patients with myelofibrosis.

AJMC interviews Jill A. Fisher, PhD, author of a new book, Adverse Events: Race, Inequality, and the Testing of New Pharmaceuticals. Her research took her inside clinical testing sites for phase 1 drug studies.

Among patients with Parkinson disease aged 60 years and younger with early motor complications, deep brain stimulation was found to provide significant improvements in social, occupational, and psychosocial function.

A new commentary outlines UK guidance about evidence regarding the appropriateness of blood component irradiation for preventing transfusion-associated graft-versus-host disease (TA-GVHD).

New real-world data shows 64% of patients with psoriatic arthritis who had previously been on a biologic stayed on secukinumab for the duration of the study.

A recent meta-analysis looked at noninvasive vagus nerve stimulation (nVNS), a nonpharmacologic method of acute pain relief for headaches.

The FDA has approved risdiplam, the first at-home, oral treatment for spinal muscular atrophy.

In the primary analysis of a phase 3 study, ruxolitinib reduced spleen length and symptoms in patients with myelofibrosis, according to results published in British Journal of Haemotology.

Researchers found that patients with idiopathic pulmonary fibrosis (IPF) are at increased risk of developing several forms of cancer compared with the general population.

A new analysis offers insights into how ozanimod works in patients with relapsing multiple sclerosis, as well as the impact of higher dosage.

Just like in clinical trials, a real-world analysis of patients with psoriatic arthritis who were treated with secukinumab achieved minimal disease activity, as well as other improvements.

Tisagenlecleucel, sold as Kymriah by Novartis, met its primary end point of complete response rate (CRR) in an interim analysis of a phase 2 study for relapsed or refractory follicular lymphoma (FL).

Patricia Salber, MD, MBA, of The Doctor Weighs In, and Sandeep “Bobby” Reddy, MD, an oncologist at Harbor-UCLA Medical Center and chief medical officer of NantHealth, discuss the clinical care of patients with cancer in the age of COVID-19.

The coronavirus disease 2019 (COVID-19) vaccines that are leading the pack are utilizing a new vaccine technology that has never been approved for human use by the FDA. As a result, there are a lot of unknowns.

The race for a coronavirus disease 2019 (COVID-19) vaccine is one of the most urgent public health challenges, with multiple vaccine candidates entering phase 3 trials and case counts around the world steadily climbing. MJH Life Sciences™ will host a free webinar with the top minds in infectious disease, virology, and vaccinology to discuss the latest trial information on vaccines.

In children with inflammatory rheumatic diseases, tocilizumab can cause serious adverse events (AEs), with children who were younger at disease onset and at time of tocilizumab initiation especially affected.

The researchers noted that these results can help inform therapeutic decision making and identify opportunities to address barriers to disease-modifying drug (DMD) adherence, which not only improves clinical outcomes but also reaps benefits when it comes to health care costs.

Transferring from pediatric to adult care can result in difficulties for patients with childhood-onset systemic lupus erythematosus.

In 2 studies of secukinumab use in real-world settings, researchers identified the usefulness of dose escalation in patients with psoriatic arthritis (PsA), as well as the safety, retention rate, and factors associated with drug survival among patients with PsA and ankylosing spondyloarthritis.

Umbilical cord blood provides a readily available source of stem cells to provide better access to hematopoietic stem cell transplantation to safely and effectively treat various noncancerous genetic disorders in children.

Comorbidities are common in patients with rheumatoid arthritis, and the presence of comorbidities reduces the chance of remission and is associated with worse functional status and disease activity measures.

Two experimental vaccines, one from AstraZeneca and the other from CanSino Biologics, have shown promising results against coronavirus disease 2019 (COVID-19) in a phase 1/2 trial and a phase 2 trial. Results for both were published in The Lancet.

Clinical trial result revealed that upadacitinib may be more effective in treating patients with rheumatoid arthritis than the gold standard of care, methotrexate.

A new oral therapy approved by the FDA will provide patients with myelodysplastic syndromes, who typically visit a health care facility for intravenous treatment, with an oral at-home option that can be beneficial during the coronavirus pandemic.

The focus on curbing COPD prevalence has largely focused on smoking cessation, but there are other factors, including diet, that can contribute to the risk of developing COPD.

Scientists do not yet have a full understanding of how multiple myeloma develops, but a new article suggests the gut microbiome is one factor that may play a role.

Investigators used death certificate data to determine the annual average decline of deaths attributed to systemic sclerosis.

Treatment options for psoriatic arthritis and axial spondyloarthritis are increasing, and with studies already identifying response predictors for tumor necrosis factor inhibitors, there is a need to predict response to the interleukin-17A inhibitor secukinumab.

Patients with systemic lupus erythematosus (SLE) may consider hydroxychloroquine essential to their treatment, but after the drug was identified as a potential therapy for coronavirus disease 2019 (COVID-19), patients with SLE experienced reduced access to the treatment, which could increase the risk of SLE flare.

FDA has lifted a partial clinical hold on a phase 2 trial of a treatment for patients with relapsed or refractory (R/R) Hodgkin lymphoma from ADC Therapeutics. The trial of camidanlumab tesirine (Cami), an antibody drug conjugate that binds to CD25, is evaluating the safety and efficacy of the therapy and is intended to support the submission of a Biologics License Application to the FDA.